Home » Stocks » BioMarin Pharmaceutical

BioMarin Pharmaceutical Inc. (BMRN)

Stock Price: $118.33 USD 1.50 (1.28%)
Updated Aug 12, 2020 11:37 AM EDT - Market open

Stock Price Chart

Key Info

Market Cap 21.46B
Revenue (ttm) 1.85B
Net Income (ttm) 122.26M
Shares Out 181.35M
EPS (ttm) 0.68
PE Ratio 174.01
Forward PE 89.29
Dividend n/a
Dividend Yield n/a

Stock Quote

Trading Day Aug 12, 2020
Last Price $118.33
Previous Close $116.83
Change ($) 1.50
Change (%) 1.28%
Day's Open 117.00
Day's Range 116.98 - 118.98
Day's Volume 318,823
52-Week Range 62.88 - 131.95

More Stats

Market Cap 21.46B
Enterprise Value 21.52B
Earnings Date (est) Oct 22, 2020
Ex-Dividend Date n/a
Shares Outstanding 181.35M
Float 180.10M
EPS (basic) 0.69
EPS (diluted) 0.68
FCF / Share 0.31
Dividend n/a
Dividend Yield n/a
Earnings Yield 0.57%
FCF Yield 0.26%
Payout Ratio n/a
Shares Short 10.54M
Short Ratio 6.10
Short % of Float 6.39%
Beta 1.05
PE Ratio 174.01
Forward PE 89.29
P/FCF Ratio 377.70
PS Ratio 11.62
PB Ratio 6.70
Revenue 1.85B
Operating Income 58.86M
Net Income 122.26M
Free Cash Flow 56.82M
Net Cash -62.93M
Net Cash / Share -0.35
Gross Margin 34.08%
Operating Margin 3.19%
Profit Margin 6.60%
FCF Margin 3.08%
ROA -0.13%
ROE 3.95%
ROIC n/a
Stats based on trailing-twelve-month (ttm) numbers.

Analyst Summary

Analyst Ratings (25)

Buy 18
Overweight 1
Hold 6
Underweight 0
Sell 0

Analyst Consensus: Buy

Price Target

$134.82*
(13.94% upside)
Low
108
Current: $118.33
High
172
Target: 134.82
*Average 12-month price target from 22 stock analysts.

Financial Performance

Financial numbers in millions USD.

Financial Overview

Year2019201820172016201520142013201220112010
Revenue1,7041,4911,3141,117890749548501441376
Revenue Growth14.27%13.52%17.62%25.5%18.77%36.61%9.54%13.45%17.3%-
Gross Profit1,3451,1761,072907738627460409357306
Operating Income-100-124-14.70-803-111-92.89-156-110-33.890.54
Net Income-23.85-77.21-117-630-172-134-176-114-53.84206
Shares Outstanding179177174166160146138120112103
Earnings Per Share-0.13-0.44-0.67-3.81-1.07-0.92-1.28-0.95-0.481.73
Operating Cash Flow48.2620.21-8.76-228-219-70.42-57.3417.6118.4218.75
Capital Expenditures-145-145-199-148-228-117-65.19-44.57-154-49.46
Free Cash Flow-96.76-124-208-376-447-187-123-26.96-136-30.72
Cash & Equivalents7541,0841,396790593945785448195274
Total Debt8488301,174683662643656348348378
Net Cash / Debt-94.31254221106-69.6730212999.58-153-103
Assets4,6904,4274,6334,0243,7292,4752,2441,5681,3061,263
Liabilities1,5681,4591,8241,2571,329947903553533545
Book Value3,1222,9682,8092,7662,4011,5281,3411,016773717
Numbers in millions USD, except per-share numbers.

Company Profile

Company Details

Full Name BioMarin Pharmaceutical Inc.
Country United States
Employees 3,001
CEO Jean-Jacques Bienaimé

Stock Information

Ticker Symbol BMRN
Stock Exchange NASDAQ
Sector Healthcare
Industry Biotechnology
Unique Identifier NASDAQ: BMRN
IPO Date July 23, 1999

Description

BioMarin Pharmaceutical Inc., a biotechnology company, develops and commercializes therapies for people with serious and life-threatening rare diseases and medical conditions. Its commercial products include Aldurazyme to treat mucopolysaccharidosis I, a genetic disease; Brineura for the treatment of late infantile neuronal ceroid lipofuscinosis type 2, a form of Batten disease; and Kuvan, a proprietary synthetic oral form of 6R-BH4 that is used to treat patients with phenylketonuria (PKU), an inherited metabolic disease. The company's commercial products also comprise Naglazyme, a recombinant form of N-acetylgalactosamine 4-sulfatase for patients with mucopolysaccharidosis VI; Palynziq, a PEGylated recombinant phenylalanine ammonia lyase enzyme for adult patients with PKU; and Vimizim, an enzyme replacement therapy for the treatment of mucopolysaccharidosis IV Type A, a lysosomal storage disorder. Its clinical and pre-clinical product pipeline includes valoctocogene roxaparvovec, an adeno associated virus vector, which is in Phase III clinical trial for the treatment of patients with severe hemophilia A; vosoritide, a peptide therapeutic that is in Phase III clinical trial for the treatment of achondroplasia, a form of disproportionate short stature in humans; and BMN 307, an AAV5 mediated gene therapy to normalize blood phenylalanine concentration levels in patients with phenylketonuria. The company serves specialty pharmacies; and end-users, such as hospitals and foreign government agencies, as well as distributors and pharmaceutical wholesalers in the United States, Europe, Latin America, and internationally. BioMarin Pharmaceutical Inc. has collaboration and license agreements with Sarepta Therapeutics and Asubio Pharma Co., Ltd.; and a preclinical collaboration and license agreement with DiNAQOR AG for the development of gene therapies to treat rare genetic cardiomyopathies. The company was founded in 1996 and is headquartered in San Rafael, California.